Board member in the pharmaceutical, medical device, oncology and ophthalmology industries. Venture investor collaborating with distinguished co-investors in life science early-stage businesses. Chairman of SLAM BioTherapeutics, an oncology company developing a platform of first-in-class antibodies, ADCs and bispecifics to impact the lives of patients with life-threatening cancers. Board member and investor in the cardiology company UltraSight Medical and ophthalmic companies NanoDrops, Lentechs, TearClear and Vinci Pharmaceuticals. In addition, have invested and advised with dozens of other life science companies. Served as executive and officer at Bausch + Lomb. CEO and board member of RxSight/Calhoun Vision which is now public. Co-authored The Merger Dividend, published in the Harvard Business Review. Featured in the Wall Street Journal, Bloomberg Businessweek, Chief Executive Magazine and Pharmaceutical Executive. Bachelor’s degree from Boston University, and a Master of Management from McGill University.